07:00 , Oct 24, 2016 |  BioCentury  |  Product Development

A new BEAT for AML

  With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a virtuous...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115)

Neurology INDICATION: Neuroinflammation Mouse studies suggest the CSF1R inhibitor PLX3397 could help treat brain injury-induced neuroinflammation. CSF1R is expressed only on microglial cells in the brain and induces their proliferation. In a mouse model of diphtheria toxin-induced...
07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) Mouse studies suggest the brain-penetrant CSF1R inhibitor BLZ945...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Array BioPharma, Celgene deal

Array received a $10 million milestone payment from Celgene under a 2007 deal granting Celgene the option to license exclusive, worldwide rights to compounds from two of four mutually selected therapeutic programs for cancer and...